regarding the STING-dependency of inflammation-driven tumorigenesis (17), we hypothesized that the suppressive activity of DMXAA on the STING pathway in human cells could be the reason for it demonstrating partial anti-tumor activity in humans and managing to reach phase III in clinical trials of NSCLC. This evidence concerns the gene STING1 and neoplasm.